Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients. - Wikidata - wikimedia - TriplyDB

Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients.

Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients.

http://www.wikidata.org/entity/Q37374502

about

Emerging novel concept of chaperone therapies for protein misfolding diseases Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment Gene therapy for neurologic manifestations of mucopolysaccharidoses.Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model Clinical Improvement of Alpha-mannosidosis Cat Following a Single Cisterna Magna Infusion of AAV1.Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.

P2860

Q27002907-4D3AA26A-EF0A-489B-974F-30C29B97C45B Q27321536-93C5C9E5-117F-4331-9954-0C96883C1093 Q35362251-985EB884-B97A-40AA-AE88-8E59E612656C Q36067812-D8C63DCE-0B46-48B4-A2CB-2A01ABB8C8BE Q36867296-36B9BE4D-DD55-4B6F-B55E-8ECD171A53A1 Q38471750-BBFE223C-957E-4D3C-8CAB-A36D23887B11 Q38853824-0C18CCF3-E380-4ED0-9CAC-A48E07FB30ED Q40219437-4012069C-D831-4922-96BE-1DA6C58596D8 Q40663776-B7908243-8981-4CCD-82E4-55C0B4CC7F95

P2860

Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients.

http://www.wikidata.org/entity/Q37374502

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immune response to intrathecal ...... opolysaccharidosis I patients.

@en

Immune response to intrathecal ...... opolysaccharidosis I patients.

@nl

type

label

Immune response to intrathecal ...... opolysaccharidosis I patients.

@en

Immune response to intrathecal ...... opolysaccharidosis I patients.

@nl

prefLabel

Immune response to intrathecal ...... opolysaccharidosis I patients.

@en

Immune response to intrathecal ...... opolysaccharidosis I patients.

@nl

P1433

Q37374502-9FAF6EB0-FAA3-4137-B527-05770913309F

P1476

Q37374502-D96646CE-34F8-4F9A-A644-1B74DE900E85

P2093

Q37374502-0FC925D3-40F9-4835-B744-5C8AB8D86611

Q37374502-451C4C97-6113-4E5E-B443-CF21EFD59BB2

Q37374502-477FB3E1-2884-4946-BD0A-03694A05A33A

Q37374502-4A9BE045-D81B-4623-8712-9B1F10281093

Q37374502-5CA96FB1-E113-4F9B-89B6-77F1EAD4030B

Q37374502-ACCC559D-DB4A-4ED8-A605-1A732DAE4C40

Q37374502-B57E4F0F-E1CD-42CA-823A-D8D0C92082AE

Q37374502-CD371828-819A-479C-9B43-F62A9B619B26

Q37374502-CFF99806-0FD7-43FE-9C55-3139469FFB26

Q37374502-FE77D96D-1E8F-4853-B5C1-59FB4A5B224E

P2860

Q37374502-13C5CD24-6316-407B-9237-C86716962788

Q37374502-166DD89B-BFED-4D59-A49A-804DE9FF9D30

Q37374502-1BBA1EDB-2AED-4400-A6F9-0FCB2B4153AF

Q37374502-23B66A3E-48BB-435D-B218-23D90A806806

Q37374502-27E94450-434C-4CA7-8FB4-5D8506D76395

Q37374502-3D9A013A-F8AF-418E-BBE9-E9B305CA5564

Q37374502-40013795-CAC9-4E71-A113-A365051E5FCD

Q37374502-47A11C3E-6148-4DBE-899A-BAD6E1C647DB

Q37374502-4A01E164-C9D4-4B56-994E-2C30A0C7B0B9

Q37374502-7737C563-24E7-4C8C-85A6-82FF3A151A6F

P2888

Q37374502-3E8AA305-E59D-45AC-A37B-7E6D3A0A4B1A

P304

Q37374502-A475FF05-4B8A-418C-BA74-02BF58634349

P31

Q37374502-B857DBFB-8B98-4131-9CE3-89653D971B9A

P356

Q37374502-BB02EF43-6871-4AA7-9996-931C023F9586

P407

Q37374502-CBB8D1F2-C801-4F83-B31D-9455C7C08394

P433

Q37374502-890C7600-6E3C-4F6B-8B2A-67A216260DEE

P478

Q37374502-74104329-AF17-4E47-9EAF-E15C28248977

P577

Q37374502-2D609191-0A6D-4D30-9B37-36DE2081FD62

P5875

Q37374502-22705338-F91C-412E-B322-344D6D330022

P698

Q37374502-3A184BB6-A2B8-41E1-891F-F889028249BD

P921

Q37374502-00491E93-300D-4010-9B34-AA427996BFB5

P932

Q37374502-AC931CC3-D3C4-451D-95F1-36A69B4887A7

P356

P1433

Pediatric Research

P1476

Immune response to intrathecal ...... opolysaccharidosis I patients.

@en

P2093

Agnes Chen

http://www.w3.org/2001/XMLSchema#string

Anton Mlikotic

http://www.w3.org/2001/XMLSchema#string

David Naylor

http://www.w3.org/2001/XMLSchema#string

Hermes Garban

http://www.w3.org/2001/XMLSchema#string

Ilkka Kaitila

http://www.w3.org/2001/XMLSchema#string

Moin Vera

http://www.w3.org/2001/XMLSchema#string

Patricia Dickson

http://www.w3.org/2001/XMLSchema#string

Paul Harmatz

http://www.w3.org/2001/XMLSchema#string

Shih-Hsin Kan

http://www.w3.org/2001/XMLSchema#string

Steven Le

http://www.w3.org/2001/XMLSchema#string

P2860

The challenge of drug-induced aseptic meningitis

Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

Original Papers: ON FROIN'S SYNDROME, AND ITS RELATION TO ALLIED CONDITIONS IN THE CEREBROSPINAL FLUID.

Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation.

Froin's syndrome revisited, 100 years on. Pseudo-Froin's syndrome on MRI.

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

Mucopolysaccharidosis type I subtypes. Presence of immunologically cross-reactive material and in vitro enhancement of the residual alpha-L-iduronidase activities.

Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

P2888

P304

712-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/PR.2013.158

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256425230

http://www.w3.org/2001/XMLSchema#string

P698

24002329

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

3855632

http://www.w3.org/2001/XMLSchema#string